nodes	percent_of_prediction	percent_of_DWPC	metapath
Naratriptan—MAOA—conduct disorder	0.894	1	CbGaD
Naratriptan—MAOA—Enzymatic degradation of Dopamine by monoamine oxidase—COMT—conduct disorder	0.013	0.131	CbGpPWpGaD
Naratriptan—MAOA—Clearance of dopamine—COMT—conduct disorder	0.00942	0.0945	CbGpPWpGaD
Naratriptan—HTR1F—Serotonin receptors—HTR2A—conduct disorder	0.00448	0.045	CbGpPWpGaD
Naratriptan—MAOA—Serotonin Transporter Activity—SLC6A4—conduct disorder	0.0044	0.0441	CbGpPWpGaD
Naratriptan—MAOA—Neurotransmitter Clearance In The Synaptic Cleft—COMT—conduct disorder	0.0043	0.0431	CbGpPWpGaD
Naratriptan—Almotriptan—MAOA—conduct disorder	0.00306	0.51	CrCbGaD
Naratriptan—HTR1F—Monoamine GPCRs—DRD4—conduct disorder	0.00306	0.0307	CbGpPWpGaD
Naratriptan—Sumatriptan—MAOA—conduct disorder	0.00295	0.491	CrCbGaD
Naratriptan—MAOA—Dopamine metabolism—COMT—conduct disorder	0.00291	0.0292	CbGpPWpGaD
Naratriptan—HTR1D—Serotonin receptors—HTR2A—conduct disorder	0.00287	0.0287	CbGpPWpGaD
Naratriptan—HTR1B—Serotonin receptors—HTR2A—conduct disorder	0.00281	0.0281	CbGpPWpGaD
Naratriptan—MAOA—Biogenic Amine Synthesis—COMT—conduct disorder	0.0026	0.0261	CbGpPWpGaD
Naratriptan—HTR1F—Amine ligand-binding receptors—DRD4—conduct disorder	0.00257	0.0258	CbGpPWpGaD
Naratriptan—HTR1A—Serotonin receptors—HTR2A—conduct disorder	0.00214	0.0214	CbGpPWpGaD
Naratriptan—HTR1F—Monoamine GPCRs—HTR2A—conduct disorder	0.002	0.02	CbGpPWpGaD
Naratriptan—HTR1D—Monoamine GPCRs—DRD4—conduct disorder	0.00196	0.0196	CbGpPWpGaD
Naratriptan—HTR1B—Monoamine GPCRs—DRD4—conduct disorder	0.00191	0.0192	CbGpPWpGaD
Naratriptan—HTR1F—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00168	0.0168	CbGpPWpGaD
Naratriptan—HTR1D—Amine ligand-binding receptors—DRD4—conduct disorder	0.00164	0.0165	CbGpPWpGaD
Naratriptan—HTR1B—Amine ligand-binding receptors—DRD4—conduct disorder	0.00161	0.0161	CbGpPWpGaD
Naratriptan—HTR1A—Monoamine GPCRs—DRD4—conduct disorder	0.00146	0.0146	CbGpPWpGaD
Naratriptan—HTR1F—GPCRs, Other—DRD4—conduct disorder	0.00136	0.0136	CbGpPWpGaD
Naratriptan—HTR1D—Monoamine GPCRs—HTR2A—conduct disorder	0.00128	0.0128	CbGpPWpGaD
Naratriptan—HTR1B—Monoamine GPCRs—HTR2A—conduct disorder	0.00125	0.0125	CbGpPWpGaD
Naratriptan—HTR1A—Amine ligand-binding receptors—DRD4—conduct disorder	0.00123	0.0123	CbGpPWpGaD
Naratriptan—HTR1D—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00107	0.0108	CbGpPWpGaD
Naratriptan—HTR1B—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00105	0.0105	CbGpPWpGaD
Naratriptan—HTR1A—Monoamine GPCRs—HTR2A—conduct disorder	0.000952	0.00955	CbGpPWpGaD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000903	0.00906	CbGpPWpGaD
Naratriptan—HTR1F—GPCRs, Other—HTR2A—conduct disorder	0.000886	0.00889	CbGpPWpGaD
Naratriptan—HTR1A—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0008	0.00802	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—CGA—conduct disorder	0.000687	0.0069	CbGpPWpGaD
Naratriptan—MAOA—Transmission across Chemical Synapses—GABRA2—conduct disorder	0.00068	0.00682	CbGpPWpGaD
Naratriptan—HTR1F—G alpha (i) signalling events—DRD4—conduct disorder	0.000636	0.00638	CbGpPWpGaD
Naratriptan—HTR1F—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00059	0.00592	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000577	0.00579	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000565	0.00567	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.000527	0.00528	CbGpPWpGaD
Naratriptan—MAOA—Neuronal System—GABRA2—conduct disorder	0.000521	0.00522	CbGpPWpGaD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000506	0.00507	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.000448	0.00449	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—CGA—conduct disorder	0.00044	0.00441	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000431	0.00432	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—CGA—conduct disorder	0.00043	0.00432	CbGpPWpGaD
Naratriptan—HTR1D—G alpha (i) signalling events—DRD4—conduct disorder	0.000407	0.00408	CbGpPWpGaD
Naratriptan—HTR1B—G alpha (i) signalling events—DRD4—conduct disorder	0.000398	0.00399	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—CGA—conduct disorder	0.000389	0.0039	CbGpPWpGaD
Naratriptan—HTR1F—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000385	0.00386	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—DRD4—conduct disorder	0.000385	0.00386	CbGpPWpGaD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000377	0.00378	CbGpPWpGaD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00037	0.00371	CbGpPWpGaD
Naratriptan—MAOA—Biological oxidations—COMT—conduct disorder	0.000369	0.0037	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—CGA—conduct disorder	0.000353	0.00354	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.000337	0.00338	CbGpPWpGaD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00033	0.00331	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—CGA—conduct disorder	0.000328	0.00329	CbGpPWpGaD
Naratriptan—MAOA—Transmission across Chemical Synapses—COMT—conduct disorder	0.000327	0.00328	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000323	0.00324	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.000323	0.00324	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000317	0.00318	CbGpPWpGaD
Naratriptan—HTR1A—G alpha (i) signalling events—DRD4—conduct disorder	0.000303	0.00304	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000281	0.00282	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.000275	0.00275	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—HTR2A—conduct disorder	0.000251	0.00252	CbGpPWpGaD
Naratriptan—MAOA—Neuronal System—COMT—conduct disorder	0.000251	0.00251	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—CGA—conduct disorder	0.000248	0.00249	CbGpPWpGaD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000246	0.00247	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—DRD4—conduct disorder	0.000246	0.00247	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—CGA—conduct disorder	0.000243	0.00244	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000241	0.00242	CbGpPWpGaD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000241	0.00242	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—DRD4—conduct disorder	0.000241	0.00242	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—CGA—conduct disorder	0.000226	0.00226	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—CGA—conduct disorder	0.000221	0.00222	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—DRD4—conduct disorder	0.000218	0.00218	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000211	0.00212	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CGA—conduct disorder	0.000208	0.00209	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000207	0.00207	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—DRD4—conduct disorder	0.000198	0.00198	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—CGA—conduct disorder	0.000185	0.00186	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000184	0.00184	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—DRD4—conduct disorder	0.000184	0.00184	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—EP300—conduct disorder	0.000171	0.00172	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CGA—conduct disorder	0.000168	0.00169	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—WASF1—conduct disorder	0.000167	0.00168	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—HTR2A—conduct disorder	0.000161	0.00161	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000157	0.00158	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—HTR2A—conduct disorder	0.000157	0.00158	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—EP300—conduct disorder	0.000146	0.00146	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—HTR2A—conduct disorder	0.000142	0.00142	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—CGA—conduct disorder	0.00014	0.0014	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—DRD4—conduct disorder	0.000139	0.0014	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—DRD4—conduct disorder	0.000136	0.00137	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CGA—conduct disorder	0.000133	0.00134	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CGA—conduct disorder	0.000131	0.00131	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—HTR2A—conduct disorder	0.000129	0.00129	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—DRD4—conduct disorder	0.000126	0.00127	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—DRD4—conduct disorder	0.000124	0.00124	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—HTR2A—conduct disorder	0.00012	0.0012	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—DRD4—conduct disorder	0.000117	0.00117	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—WASF1—conduct disorder	0.000107	0.00107	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—WASF1—conduct disorder	0.000105	0.00105	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—DRD4—conduct disorder	0.000104	0.00104	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CGA—conduct disorder	9.94e-05	0.000997	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—DRD4—conduct disorder	9.42e-05	0.000945	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—HTR2A—conduct disorder	9.08e-05	0.000911	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—HTR2A—conduct disorder	8.89e-05	0.000892	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—HTR2A—conduct disorder	8.24e-05	0.000827	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—HTR2A—conduct disorder	8.07e-05	0.00081	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—WASF1—conduct disorder	7.97e-05	0.000799	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—HTR2A—conduct disorder	7.62e-05	0.000764	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—DRD4—conduct disorder	7.46e-05	0.000749	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—DRD4—conduct disorder	7.31e-05	0.000733	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—HTR2A—conduct disorder	6.77e-05	0.000679	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—COMT—conduct disorder	6.31e-05	0.000633	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—HTR2A—conduct disorder	6.15e-05	0.000617	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—DRD4—conduct disorder	5.57e-05	0.000558	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—HTR2A—conduct disorder	4.87e-05	0.000488	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—HTR2A—conduct disorder	4.77e-05	0.000478	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—EP300—conduct disorder	4.03e-05	0.000405	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—HTR2A—conduct disorder	3.63e-05	0.000364	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—EP300—conduct disorder	2.71e-05	0.000272	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—EP300—conduct disorder	2.58e-05	0.000259	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—EP300—conduct disorder	2.53e-05	0.000253	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—EP300—conduct disorder	1.92e-05	0.000193	CbGpPWpGaD
